Novartis Ianalumab Combination Shows 45% Improvement in ITP Disease Control in Phase III Trial
Key Insights
Novartis reported positive Phase III VAYHIT2 trial results showing ianalumab plus eltrombopag prolonged immune thrombocytopenia disease control by 45% compared to placebo.
The combination therapy achieved a median time to treatment failure of 13.0 months, 2.8 times longer than the 4.7 months observed with placebo plus eltrombopag.
Multiple pharmaceutical companies are advancing ITP treatments through clinical trials, with over 30 companies developing 30+ pipeline therapies for this autoimmune bleeding disorder.
Novartis has reported positive findings from its Phase III VAYHIT2 trial evaluating ianalumab in combination with eltrombopag for patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids. The combination therapy demonstrated a 45% improvement in disease control based on the primary endpoint of time to treatment failure (TTF), which reflects the duration patients maintain safe platelet levels during and following treatment.
Significant Clinical Outcomes
The trial results, announced on December 9, 2025, showed that patients receiving ianalumab (9 mg/kg) plus eltrombopag achieved a median TTF of 13.0 months—2.8 times longer than the 4.7 months observed with placebo plus eltrombopag. This represents a substantial improvement in maintaining therapeutic platelet counts for patients with this autoimmune bleeding disorder.
Expanding Clinical Pipeline Activity
The ITP treatment landscape is experiencing significant activity, with multiple pharmaceutical companies advancing novel therapies through clinical trials. On December 2, 2025, argenx initiated a Phase III study evaluating efgartigimod IV in participants with primary ITP. The study design includes a double-blinded treatment period followed by open-label treatment phases, with participants potentially remaining in the study for up to 138 weeks.
Incyte Corporation launched a Phase 2A study on December 9, 2025, to evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders. Additionally, Eli Lilly and Company announced on December 4, 2025, a study investigating pirtobrutinib administered orally in participants with primary ITP, with Phase 1 focusing on tolerability and Phase 2 examining efficacy and safety of multiple dosages versus placebo.
Disease Background and Therapeutic Targets
Immune thrombocytopenia, formerly known as idiopathic thrombocytopenic purpura, is an autoimmune bleeding disorder characterized by abnormally low levels of platelets. The condition manifests as bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae).
Emerging Therapeutic Approaches
Several investigational therapies are targeting different mechanisms in ITP treatment. Rozanolixizumab (UCB7665) from UCB (search) is a humanized high-affinity anti-human neonatal Fc receptor (FcRn (search)) monoclonal antibody that aims to improve IgG-mediated autoimmune diseases by reducing pathogenic autoantibody levels through blocking IgG recycling. The drug received orphan drug designation from the FDA on April 30, 2018, and from the European Commission on January 11, 2019.
Efgartigimod from arGEN-X represents a first-in-class investigational antibody fragment designed to target the neonatal Fc receptor (FcRn (search)). The therapy is being evaluated for patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G autoantibodies, addressing areas of severe unmet medical need.
Robust Development Pipeline
According to DelveInsight's analysis, the ITP pipeline includes over 30 active companies developing more than 30 pipeline therapies. Leading companies in this space include Corcept Therapeutics, UCB (search), arGEN-X, HanAll Biopharma (search)/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, and Cour Pharmaceutical Development.
Promising pipeline therapies span various molecular approaches, including Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, and TQB3473 Tablets. These treatments encompass different routes of administration including oral, parenteral, intravitreal, subretinal, and topical formulations, with molecule types ranging from monoclonal antibodies and peptides to small molecules and gene therapy approaches.